Systematic Review of N-of-1 Studies in Rare Genetic Neurodevelopmental Disorders

Author:

Müller Annelieke R.ORCID,Brands Marion M.M.G.,van de Ven Peter M.,Roes Kit C.B.ORCID,Cornel Martina C.ORCID,van Karnebeek Clara D.M.ORCID,Wijburg Frits A.,Daams Joost G.ORCID,Boot ErikORCID,van Eeghen Agnies M.ORCID

Abstract

ObjectiveTo improve the use of N-of-1 studies in rare genetic neurodevelopmental disorders, we systematically reviewed the literature and formulated recommendations for future studies.MethodsThe systematic review protocol was registered in the PROSPERO International Prospective Register of Systematic Reviews (CRD42020154720). EMBASE and MEDLINE were searched for relevant studies. Information was recorded on types of interventions, outcome measures, validity, strengths, and limitations using standard reporting guidelines and critical appraisal tools. Qualitative and descriptive analyses were performed.ResultsTwelve studies met the N-of-1 inclusion criteria, including both single trials and series. Interventions were mainly directed to neuropsychiatric manifestations. Main strengths were the use of personalized and clinically relevant outcomes in most studies. Generalizability was compromised due to limited use of validated and generalizable outcome measures.ConclusionN-of-1 studies are sporadically reported in rare genetic neurodevelopmental disorders. Properly executed N-of-1 studies may provide a powerful alternative to larger randomized controlled trials in rare disorders and a much needed bridge between practice and science. We provide recommendations for future N-of-1 studies in rare genetic neurodevelopmental disorders, ultimately optimizing evidence-based and personalized care.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical)

Reference57 articles.

1. European Parliament C of the EU. Regulation (EC) N°141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products 2000. Official Journal of the European Communities. Available at: ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2000_141_cons-2009-07/reg_2000_141_cons-2009-07_en.pdf. Accessed February 20, 2020.

2. European Organisation for Rare Diseases (EURORDIS): Rare Diseases: Understanding This Public Health Priority. 2005. Available at: eurordis.org/IMG/pdf/princeps_document-EN.pdf. Accessed February 20, 2020.

3. Labeling of disease-modifying therapies for neurodegenerative disorders;Morant;Front Med,2019

4. Inborn errors of metabolism: advances in diagnosis and therapy;Vernon;JAMA Pediatr,2015

5. A clinician's guide for conducting randomized trials in individual patients;Guyatt;Can Med Assoc J,1988

Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3